• Imidazoline Antagonists Stimulate Insulin by Blocking β-Cell

  2026-08-02

  Jonas et al. (1992) demonstrated that imidazoline antagonists of α2-adrenoceptors, such as phentolamine, increase insulin secretion in pancreatic β-cells by directly inhibiting ATP-sensitive potassium channels, rather than through α2-adrenoceptor blockade. This mechanistic insight redefines how imidazoline derivatives may be leveraged in diabetes research and clarifies the interplay between adrenergic signaling and β-cell ion channel regulation.

• Diphenyleneiodonium Chloride: Empowering Redox and cAMP Rese

  2026-08-01

  Diphenyleneiodonium chloride (DPI) from APExBIO stands out as a dual-function probe for dissecting redox enzyme activity and modulating cAMP signaling. This article details robust experimental workflows, troubleshooting strategies, and key innovations, enabling reproducible results across oxidative stress, pathogen resistance, and GPCR research.

• Prestained Protein Marker (Triple color, EDTA free, 10-250 k

  2026-07-31

  The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) addresses the need for accurate, visible molecular weight standards during SDS-PAGE and Western blot workflows, facilitating real-time monitoring and transfer verification without additional sample preparation. It should not be used for absolute protein quantitation or in workflows requiring EDTA-containing markers.

• GSK2606414: Precision PERK Inhibitor for ER Stress Research

  2026-07-31

  GSK2606414 enables precise, nanomolar-level inhibition of PERK, making it the gold standard for dissecting unfolded protein response mechanisms in ER stress research. Leveraging insights from recent disease models and robust protocol optimizations, this article guides researchers in maximizing data quality and troubleshooting common pitfalls.

• Mitochondrial Apoptosis and Muscle Atrophy in Ovarian Cancer

  2026-07-30

  This study demonstrates that targeting mitochondrial-linked apoptosis with the antioxidant SkQ1 reduces caspase-9 and -3 activity in skeletal muscle during ovarian cancer, but does not prevent muscle atrophy. The findings suggest mitochondrial ROS regulate apoptotic caspases, but neither apoptosis nor necroptosis in type II B fibers are singularly responsible for cancer-associated muscle loss.

• Perphenazine: Dopamine D2 Antagonist for Research Applicatio

  2026-07-30

  Perphenazine is a dopamine D2 receptor antagonist with verified efficacy in neuropharmacology and host-pathogen interaction research. It induces mitochondria-mediated cell death, suppresses opioid tolerance in animal models, and enhances macrophage antibacterial activity. These properties establish its utility for schizophrenia, psychosis, and antibacterial studies.

• CCR7–Notch1 Crosstalk Drives Stemness in Mammary Tumor Cells

  2026-07-29

  Boyle et al. (2017) uncover a functional intersection between CCR7 and Notch1 signaling pathways in mammary cancer stem-like cells, showing that their interplay sustains stemness and may promote tumor progression. These findings provide a mechanistic basis for dual targeting strategies in breast cancer therapy, with implications for experimental designs requiring high-purity nucleic acid workflows.

• Staurosporine in Cancer Metastasis: Beyond Apoptosis Inducti

  2026-07-29

  Explore how Staurosporine, a broad-spectrum serine/threonine protein kinase inhibitor, reshapes cancer metastasis research by revealing new insights into cell death, reprogramming, and tumor microenvironment dynamics. This in-depth analysis bridges recent molecular findings to practical assay decisions.

• Cholesterol-Dependent LRRC8A–Caveolin-1 Axis in PDAC Growth

  2026-07-28

  The referenced study uncovers how the LRRC8A–Caveolin-1 complex, dependent on cholesterol-rich membrane domains, sustains KRAS/EGFR oncogenic signaling and ribosome biogenesis in pancreatic ductal adenocarcinoma (PDAC). These insights establish a mechanistic link between cell volume regulation, oncogenic pathways, and tumor biosynthetic expansion, advancing potential therapeutic strategies for PDAC.

• Light-Inducible RNA Switches Enable Precise Gene Therapy Con

  2026-07-28

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that allows reversible, tissue-specific translational regulation of therapeutic genes in vivo. This innovation provides a foundation for safer, on-demand gene therapies, with successful demonstrations in metabolic and retinal disease models.

• Scenario-Driven Solutions with Mubritinib (TAK 165) in AML &

  2026-07-27

  This article provides an expert, scenario-driven guide for leveraging Mubritinib (TAK 165) (SKU B1543) in cell viability, proliferation, and cytotoxicity assays. Integrating literature-backed protocols and real-world troubleshooting, it demonstrates how Mubritinib delivers reproducible and selective inhibition of mitochondrial complex I for acute myeloid leukemia and primary effusion lymphoma studies.

• Go 6983: Potent Pan-PKC Inhibition for Cell Fate Research

  2026-07-27

  Go 6983 is a selective pan-PKC inhibitor that targets multiple PKC isoforms with nanomolar potency, enabling precise dissection of PKC signaling in cancer, cell differentiation, and EMT models. The compound’s solubility profile and validated use in cell- and animal-based assays make it a benchmark tool for PKC pathway research.

• Vernakalant Hydrochloride: Applied Workflows for Rapid AF Co

  2026-07-26

  Vernakalant Hydrochloride (RSD1235) delivers rapid, atrial-selective conversion of atrial fibrillation, streamlining both preclinical and translational workflows. Experimental versatility, ion channel specificity, and robust safety data set it apart for reliable, reproducible AF research.

• Canagliflozin Hemihydrate: Precision SGLT2 Inhibitor for Res

  2026-07-25

  Canagliflozin hemihydrate empowers metabolic and diabetes research with high-purity, selective SGLT2 inhibition, free from mTOR pathway confounds. This guide delivers actionable protocols, troubleshooting strategies, and key workflow enhancements to unlock reproducible, high-fidelity results.

• Trametinib (GSK1120212): Precision Oncology Tool for Heterog

  2026-07-24

  Explore Trametinib (GSK1120212) as a precision research tool for dissecting therapeutic heterogeneity in cancer models. This in-depth analysis uniquely connects MEK inhibition to practical assay design and advances in personalized oncology.

447 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page